The Biotechnology Industry Organization (BIO) is a strong supporter of effective capital markets, and we hope the April 14 guest commentary, "Reducing the Burden of Disclosure," will draw attention to these important issues. It is critically important for innovative biotechnology companies that do not yet have product revenue to focus investor dollars on the search for cures and breakthrough medicines rather than divert these funds for cumbersome disclosure requirements.

We were very supportive of the Jumpstart Our Business Startups (JOBS) Act, and continue to be deeply engaged in its implementation. In the two years since its passage, more than 80 biotech companies have gone public using provisions included within the JOBS Act.